KYMR – kymera therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 [Yahoo! Finance]
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate [Yahoo! Finance]
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader [Yahoo! Finance]
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Kymera Therapeutics (NASDAQ:KYMR) was given a new $133.00 price target on by analysts at Barclays PLC.
Form 4 Kymera Therapeutics, For: Jan 20 Filed by: Esposito Pamela
Form 144 Kymera Therapeutics, Filed by: Esposito Pamela
Form 8-K Kymera Therapeutics, For: Jan 13
Form SCHEDULE 13G/A Kymera Therapeutics, Filed by: FMR LLC
Form 4 Kymera Therapeutics, For: Jan 05 Filed by: Mainolfi Nello
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.